Skip to main content
Fig. 2 | BMC Psychiatry

Fig. 2

From: Secular trends and regional variations in pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany

Fig. 2

Prevalence of at least one prescription of any (A) and specific medication (B) in the years 2009 to 2016. The curves were fitted using a cubic spline function. Panel A: vertical lines refer to the introduction of prescription restrictions issued by the Federal Joint Committee (G-BA) in the respective years. Panel B: Dexamfetamine, lisdexamfetamine and guanfacine were licensed in the years 2012, 2013 and 2016 in Germany, respectively

Back to article page